Kardia Leung | People | Arnold & Porter

Kardia Leung advises on a wide range of corporate and commercial transactions, including mergers and acquisitions (both domestic and cross-border), debt capital markets, secondary transactions, joint ventures, restructurings and fundraisings, as well as general corporate advisory work. Ms Leung has represented clients across a range of industries, including some of the world's most sophisticated biotechnology and pharmaceutical companies.

Ms Leung also advises charitable organisations on a wide range of pro bono matters, including one which was shortlisted for the Legal Week Innovation Awards 2020 in the "Corporate Social Responsibility Innovation (Multi-Firm)" category.

Ms Leung is passionate about promoting social mobility in the legal profession and is involved in running the London Office’s Accelerate Work Experience Scheme as well as mentoring a number of students through the firm’s alliance with the Social Mobility Business Partnership.

Focus Areas

Experience

Omega Healthcare Investors, Inc., in a number of high-value transactions concerning its acquisition and lease of healthcare facilities across the UK and Jersey and general corporate advisory work.
Mark G. Anderson Consultants Inc., on its acquisition of London-based property and construction consultants Robinson Low Francis LLP.
Better HoldCo Inc., a US-based digital homeownership platform, in its acquisition of the UK-based digital mortgage and insurance broker Trussle.

Amicus Therapeutics, Inc., on its $400 million debt financing with Hayfin Capital Management.
New York-Based Private Equity Firm, in a series of secondary market purchases.
UK-Based Pension Fund, on its secondary market sale to two separate buyers involving the disposal of around 40 partnership interest, for a combined value in excess of $237 million.
Pfizer, in relation to the spin-off and combination with Mylan NV of Pfizer's established medicines division Upjohn, to form Viatris, a company with combined revenues of $20 billion.

Pfizer, in relation to supply agreements to governmental authorities concerning the roll-out of Pfizer and BioNTech’s mRNA-based vaccine, Corminaty® BNT162b2, against SARS-CoV-2.
AstraZeneca, in agreements with governmental authorities for the distribution of the University of Oxford's COVID-19 vaccine.
Pfizer, on its collaboration agreement with Entia Limited to develop a home blood monitoring system, Affinity™, for breast cancer patients.
Norgine, on its exclusive licence and distribution agreement for PLENVU® in China with Beijing Podconley Pharmaceutical Technology & Development Co., Ltd., a Chinese pharmaceutical company.

Corporación Andina de Fomento in connection with its listing of $650 million Notes due 2027 on the London Stock Exchange.
Hungary, in connection with its listing of the following Notes on the London Stock Exchange:
- $2.25 billion Notes due 2031, $2 billion Notes due 2051 and €1 billion notes due 2028
- $1.75 billion Notes due 2029, $1.25 billion Notes due 2034 and EUR 750 million Notes due 2031
The Republic of Turkey, on its Sukuk offerings including:
- $3 billion Sukuk offering (2022)
- $2.5 billion Sukuk offering (2021)

Kids in Need of Defense UK (KIND), in securing the regularized immigration status of a family that fled Nigeria for the UK.
Open Climate Fix, on its agreement with National Grid for its innovative nowcasting project, a machine learning research project used to improve grid forecasting of solar generation.
Spark Inside, in a number of general commercial and corporate advisory matters.